Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

GTB-5550

Bispecific antibody · Immune activation, directed at B7-homologue 3 (CD276) and CD16 (FCGR3A)

Phase 1 Most advanced trial
1 Registered trials

What is GTB-5550?

GTB-5550 is a trispecific NK cell engager comprising nanobodies against CD16 and B7-H3, plus human IL-15. It binds B7-H3 on tumor cells and CD16 on NK cells, bringing them together to induce NK cell cytotoxicity. IL-15 promotes NK cell proliferation and survival. It is studied in advanced solid tumors.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Bispecific antibody
Targets
B7-homologue 3 (CD276), CD16 (FCGR3A)
Mechanism
Immune activation, directed at B7-homologue 3 (CD276) and CD16 (FCGR3A)
Pathways
NK cell activation, NK cell proliferation
Therapy area
Oncology
In trials of
GTBP
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07541573 Phase 1 Tri-specific Killer Engager Recruiting GTBP

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Solid TumorSolid TumorTri-specific Killer Engager

Other drugs acting on CD276 / FCGR3A

Ac-AKY-2519 Phase 1 Acimtamig Phase 2 Ifinatamab Deruxtecan Phase 2

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.